I-Mab reports efficacy of Anti-CD47 monoclonal Ab on relapsed/refractory malignancy
Clinical Trial Phase | Company results | 0 Comment | 25 Nov, 2020
I-Mab, a global clinical-stage biopharmaceutical company based in China and the US and committed to the discovery, devel...Read more
Gilead’s Biktarvy sustains viral suppression and tolerability in Asian HIV patients
Clinical Trial Phase | News | 0 Comment | 16 Oct, 2020
Gilead Sciences, Inc. on 15 Oct 2020 announced findings from multiple studies in Asian population that evaluated th...Read more